Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | SLC16A7 | O60669 | 1/20 | 0.42 |
| ▸ | PDE1A | P54750 | 1/20 | 0.40 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.40 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5405288 | 0.90 | SLC16A1 (0.47) | SLC16A1TP53MAPTCYP3A4CYP2C9 | |
| SCHEMBL5395864 | 0.88 | SLC16A1 (0.47) | SLC16A1 | |
| SCHEMBL5405554 | 0.88 | SLC16A1 (0.47) | SLC16A1CYP3A4CYP2C9SLC16A7 | |
| SCHEMBL5418116 | 0.87 | SLC16A1 (0.46) | SLC16A1 | |
| SCHEMBL5400652 | 0.87 | MAPT (0.48) | SLC16A1TP53MAPTPDE1APDE1B | |
| SCHEMBL5405716 | 0.86 | TP53 (0.44) | SLC16A1TP53MAPTPDE1APDE1B | |
| SCHEMBL6659477 | 0.83 | TP53 (0.41) | TP53MAPTPDE1APDE1BPDE1C | |
| SCHEMBL5411378 | 0.83 | TP53 (0.45) | TP53MAPTPDE1APDE1BPDE1C | |
| SCHEMBL5407653 | 0.83 | TP53 (0.40) | TP53MAPTPDE1APDE1BPDE1C | |
| SCHEMBL5400727 | 0.83 | TP53 (0.39) | TP53MAPTPDE1APDE1BPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | DPYD, HPGDS, PGC | SLC16A1 4140/4885TP53 1580/4885MAPT 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.